Transgenic DNA modules with pre-programmed self-destruction: Universal molecular devices to escape 'genetic litter' in gene and cell therapy

Medical Hypotheses
Oleg E Tolmachov

Abstract

Gene delivery to human somatic cells is a well-established therapeutic strategy to treat a variety of diseases. In addition, gene transfer to human cells is required to generate human induced pluripotent cells and also to eliminate tumorigenic undifferentiated cells in many types of stem-cell derived transplantation material. The expression of transgenes in these medical technologies is often required only in some of the recipient cells and only in specific limited time-windows, with inappropriately located or untimely expressed transgenes presenting a risk of undesired collateral effects. Unfortunately, current gene transfer procedures commonly result in a number of cells in the patient's body containing fragments of transferred genetic material which are either not therapeutically necessary at all, are no longer necessary or are necessary but in some other cells. Such transgenic material in the patient, created as a by-product of the chosen therapeutic procedure, constitutes, in fact, 'genetic litter', that is, persisting potentially-hazardous foreign genetic material which is neither required therapeutically nor explicitly chosen by an informed and free-willing person as an artificial body element. Wider use and more frequen...Continue Reading

References

Aug 1, 1996·Artificial Intelligence in Medicine·J DownsS S Cross
Jan 4, 2003·Blood·Christopher BaumChristof von Kalle
Apr 28, 2006·Nature·Niels-Bjarne WoodsInder M Verma
Feb 7, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Zhi-Ying ChenMark A Kay
Nov 13, 2008·Expert Reviews in Molecular Medicine·Gregory J AtkinsBrian J Sheahan
Nov 30, 2011·Journal of Nanobiotechnology·Anil Mahapatro, Dinesh K Singh
Jan 6, 2012·PloS One·Sara P Garcia, Armando J Pinho
Feb 9, 2012·Journal of Molecular Biology·James AllanDavid Keszenman-Pereyra
Jun 30, 2012·Science·Martin JinekEmmanuelle Charpentier
Jul 26, 2012·Current Gene Therapy·Andreas N KuhnUgur Sahin
Jan 5, 2013·Science·Le CongFeng Zhang
Mar 6, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jiamiao LuMark A Kay
Mar 9, 2013·Nature Biotechnology·Claudio Mussolino, Toni Cathomen
Feb 15, 2014·American Journal of Surgery·S Peter StawickiUNKNOWN OPUS 12 Foundation Multicenter Trials Group
May 3, 2014·International Journal of Cancer. Journal International Du Cancer·Sarah E Jackson, John D Chester
May 30, 2014·Nature·Pietro GenoveseLuigi Naldini
Jun 11, 2014·Nature Communications·Roberto GaliziAndrea Crisanti
Jun 25, 2014·Biomaterials·Francisco M Martin-SaavedraNuria Vilaboa
Nov 12, 2014·Nature Communications·Marc FolcherMartin Fussenegger
Dec 24, 2014·Scientific Reports·Toru SuzukiAnthony C F Perry

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR Genome Editing & Therapy

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of this system for gene editing and therapy in human diseases.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CRISPR in Cancer

CRISPR-Cas system enables the editing of genes to create or correct mutations. Given that genome instability and mutation is one of the hallmarks of cancer, the CRISPR-Cas system is being explored to genetically alter and eliminate cancer cells. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.